New to HBW Insight?
Start a free trial today!
Register for our free email digests:
Register for our free email digests:
Brought to you by

Alcon buys EsbaTech for $150mm in cash; $439mm earn-out
23 Oct 2009
Executive Summary
Alcon has agreed to buy closely held EsbaTech AG (cancer, inflammation, and neurology therapeutics) for $150mm in cash. EsbaTech shareholders may also receive up to $439mm in earn-outs based on the achievement of R&D milestones.
Deal Industry
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
-
Biotechnology
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- Genomics-Proteomics
-
Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com